Evicenter
P&T meetings

Atebrioz (zilurgisertib)

Fibrodysplasia ossificans progressiva

Also known as INCB000928
Regulatory submission
NDA submitted by May 2026
Last updated
96 sources

Company-reported prevalence

Atebrioz

Overview

FieldValue
DrugAtebrioz (zilurgisertib)
IndicationFibrodysplasia ossificans progressiva
DiseaseFibrodysplasia ossificans progressiva (FOP)
CompanyIncyte Corporation (developer and licensor); Mirum Pharmaceuticals, Inc. (exclusive licensee of worldwide development and commercialization rights since April 2026)
Documents searchedMirum Pharmaceuticals corporate website, therapeutic focus and pipeline pages (October 2026); Atebrioz patient website, healthcare professional website, and patient brochure (October 2026); Mirum Pharmaceuticals press releases of May 6, 2026, August 5, 2026, and September 25, 2026; Mirum Pharmaceuticals and Incyte joint press releases of June 4, 2026, June 14, 2026, and September 25, 2026; Mirum Pharmaceuticals Form 8-K of September 25, 2026; Mirum Pharmaceuticals Form 10-K for 2025 (February 2026); Mirum Pharmaceuticals Form 10-Q for the quarter ended June 30, 2026 (August 2026); Mirum Pharmaceuticals corporate presentation (October 2026); Mirum Pharmaceuticals ENDO 2026 oral presentation (June 2026); Incyte corporate website, pharmaceutical portfolio page (October 2026); Incyte investor relations press release list (October 2026); Incyte Form 10-K for 2025 (February 2026); Incyte second-quarter 2026 results press release (July 2026); Incyte corporate presentations (January 2026, April 2026, and July 2026)
Data as ofOctober 14, 2026
Prepared byAI research agent (Claude); not yet reviewed by a person

Company statements of prevalence

United States

Number affected: Mirum Pharmaceuticals and Incyte press release, September 2026

“Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, progressive genetic disease affecting approximately 300 people in the United States” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Mirum Pharmaceuticals and Incyte (2026) FDA approval press release, September 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number diagnosed: Mirum Pharmaceuticals corporate presentation, October 2026

“~300 U.S. diagnosed Patients” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Mirum Pharmaceuticals (2026) corporate presentation, October 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 45 of 79 (opens in a new tab)

Europe

No evidence found.

Global

Number affected (worldwide): Mirum Pharmaceuticals and Incyte press release, September 2026

“Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, progressive genetic disease affecting approximately 300 people in the United States and 900 worldwide.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Mirum Pharmaceuticals and Incyte (2026) FDA approval press release, September 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number diagnosed (worldwide): Mirum Pharmaceuticals corporate presentation, October 2026

“~900 WW diagnosed prevalence” (opens the source at this quote in a new tab)

Cited source: 2.1 International FOP Association 2026

Mirum Pharmaceuticals (2026) corporate presentation, October 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 45 of 79 (opens in a new tab)

Prevalence: Mirum Pharmaceuticals website, October 2026

“FOP is estimated to affect approximately 1 per 1 million people worldwide.” (opens the source at this quote in a new tab)

Cited source: 2.2 Pignolo 2021

Mirum Pharmaceuticals (2026) therapeutic focus website, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab), shown after selecting Rare genetic diseases, then Fibrodysplasia Ossificans Progressiva (FOP)

Other countries and regions

No evidence found.

Geography not stated

No evidence found.

Sources the company cites

International FOP association 2026

Reference as the company lists it

“International FOP Association (IFOPA). What is FOP? 2026. Available from: https://www.ifopa.org/what_is_fop.” (opens the source at this quote in a new tab)

Mirum Pharmaceuticals (2026) corporate presentation, October 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 45 of 79 (opens in a new tab)

Passage carrying the figure

“Approximately 900 confirmed cases worldwide” (opens the source at this quote in a new tab)

International FOP Association (2026) What is FOP? website, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Pignolo 2021

Reference as the company lists it

“Pignolo RJ, Hsiao EC, Baujat G, Lapidus D, Sherman A, Kaplan FS. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J Rare Dis. 2021;16(1):350. Published 2021 Aug 5. doi:10.1186/s13023-021-01983-2” (opens the source at this quote in a new tab)

Mirum Pharmaceuticals (2026) therapeutic focus website, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab), shown after selecting Rare genetic diseases, then Fibrodysplasia Ossificans Progressiva (FOP)

Passage carrying the nearest figure

“Taking into account the limitations described above, we report an estimated minimum prevalence of 0.88 per million individuals (1 in 1.14 million people) living in the United States.” (opens the source at this quote in a new tab)

Pignolo 2021, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

References

  1. International FOP Association (2026) What is FOP? website (opens in a new tab)
  2. Mirum Pharmaceuticals (2026) corporate presentation, October 2026 (opens in a new tab)
  3. Mirum Pharmaceuticals (2026) therapeutic focus website (opens in a new tab)
  4. Mirum Pharmaceuticals and Incyte (2026) FDA approval press release, September 2026 (opens in a new tab)
  5. Pignolo 2021 (opens in a new tab)